Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02356874
Other study ID # 97026: The ESpA study
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 2015
Est. completion date September 2017

Study information

Verified date February 2017
Source Diakonhjemmet Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall aim of this multicenter randomised controlled trial (RCT) is to investigate if exercise can modify the disease course and prevent comorbidity in patient with spondyloarthritis (SpA).


Description:

International guidelines recommend exercise as a cornerstone in the management of SpA. Due to the typical features of SpA with reduced spinal mobility, the main focus for exercise has been flexibility exercise. Exercise trials for this patient group have mainly aimed at improving spinal mobility and there is limited evidence of the potential effects of exercise on disease pathogenesis and CVD risk factors.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date September 2017
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

1. Diagnosis of axial SpA (the Assessment of SpondyloArthritis International Society classification criteria) confirmed by a rheumatologist

2. Age, 18-70 -years

3. Steady medication for =3 months

4. Moderate disease activity defined as a BASDAI score of =3.5 or a patient global score =3.5

5. Not participated in a structured endurance and strength exercise program during the last 6 months (>1 hour/week)

Exclusion Criteria:

1. Severe co-morbidity which involves reduced exercise capacity and/or contraindications for physical activity as per American College of Sports Medicine guidelines for exercise testing

2. Not able to participate in weekly exercises sessions

3. Pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Exercise
An exercise program for 40-60 minutes three times a week in 3 months. Twice a week the exercise sessions will be supervised by a physiotherapist and these sessions will consist of endurance and strength training. The endurance training will be high intensity interval training on a treadmill. And strength training with external load for the major muscle groups (individually adapted: six exercises, eight to ten repetitions maximum, two to three sets). Once a week the participants will exercise individually for a minimum of 40 minutes of endurance exercise.

Locations

Country Name City State
Norway Martina Hansens Hospital AS Bærum
Norway Diakonhjemmet Hospital AS Oslo
Norway University Hospital of North Norway Tromsø
Sweden University of Gotenburg Gotenburg

Sponsors (3)

Lead Sponsor Collaborator
Diakonhjemmet Hospital Norwegian School of Sport Sciences, University of Oslo

Countries where clinical trial is conducted

Norway,  Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Disease activity The Ankylosing Spondylitis Disease Activity Score (ASDAS) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 3 months
Secondary Blood samples General and specific markers of inflammation and cardiovascular risk 3 months (all analyses) 12 months (only CRP and ESR)
Secondary Spinal mobility The Bath Ankylosing Spondylitis Metrology Index (BASMI). BASMI includes five measurements of flexibility in the spine, neck and hips. 3 months
Secondary Physical function The Bath Ankylosing Spondylitis functional Index (BASFI). 3 months and 12 months
Secondary Cardiorespiratory fitness Maximal walking test on a treadmill for estimation of maximal oxygen uptake. 3 months
Secondary Body composition Body weight, body height, waist and hip circumference. DXA scan of a sample of patients. 3 months
Secondary Arterial stiffness Pulse wave velocity and argumentation Index 3 months
Secondary Endothelial function Digital plethysmography using the non-invasive ADMAR apparatus (sample of participants) 3 months
Secondary Blood pressure 3 months
Secondary General health Assessed with the general health questionnaire (GHQ-12) 3 months and 12 months
Secondary Health related quality of life Euro Quol 5D (EQ5D) 3 months and 12 months
Secondary Physical activity level Questionaire of frequency, intensity and duration of physical activity 3 months and 12 months
Secondary Self-efficacy for physical activity Questionnaire 3 months and 12 months
Secondary Fatigue The fatigue severity scale and the SF-36 vitality scale (version 1) 3 months and 12 months
Secondary Sleep Pittsburgh Sleep Quality Index (PSQI) 3 months and 12 months
See also
  Status Clinical Trial Phase
Completed NCT05031767 - Remote Monitoring of Axial Spondyloarthritis N/A
Completed NCT05162937 - to Evaluate the Preliminary Efficacy and Safety of GR1501 Injection in Patients With Active Axial Spondyloarthritis Phase 2
Completed NCT03622658 - Efficacy and Safety of Namilumab for Moderate-to-severe Axial Spondyloarthritis Phase 2
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Terminated NCT02437162 - A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis Phase 3
Enrolling by invitation NCT06072859 - The Impact of Simulated Forest Immersion Therapy on Pain and Anxiety in Patients Axial Spondyloarthritis (axSpA) N/A
Completed NCT02552212 - Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS Phase 3
Active, not recruiting NCT02687620 - Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study
Active, not recruiting NCT01944163 - The IMPACT of a Referral Model for Axial Spondyloarthritis in Young Patients With Chronic Low Back Pain N/A
Completed NCT00844805 - Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1) Phase 3
Terminated NCT02897115 - A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment Phase 4
Completed NCT05019547 - The Turkish Version of the Inflammatory Arthritis Facilitators and Barriers to Physical Activity
Recruiting NCT03738956 - Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical Trial Phase 2/Phase 3
Completed NCT04679649 - Physiotherapy of Axial Spondyloarthritis N/A
Enrolling by invitation NCT02962479 - Is the Human Microbiome Altered in Patients With Axial Spondyloarthritis? N/A
Completed NCT04485078 - Investigation of Central Sensitization Frequency and Related Factors in Axial Spondyloarthritis Patients
Recruiting NCT05812157 - Optimizing Anti-IL17 Antibody Therapy by Associating Fiber Supplementation to Correct Treatment-aggravated Gut Dysbiosis in Axial Spondyloarthritis - RESPOND-IL17 N/A
Completed NCT03039088 - PREDICT-SpA - French Epidemiological Study of the Evaluation of the Impact of Fibromyalgia in the TNF Alpha Treatment Effect in Axial Spondyloarthritis in Both Anti-TNF naïve and - Experienced Patients
Completed NCT04368494 - Exercise Therapy in Patients With Axial Spondyloarthritis N/A
Completed NCT03270501 - Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation Phase 3